Ian Krop, MD, PhD – Yale University
This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (mBC) using data from the DESTINY-Breast01, -02, and -03 trials. The analysis aimed to evaluate the efficacy and safety of T-DXd across different age groups. The results provide valuable insights into the use of T-DXd in HER2-positive mBC patients of varying ages.